Europe Glycobiology Market Research Report - Segmented By Product, Application, End User & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 6746
Pages: 145

Europe Glycobiology Market Size & Growth (2023 to 2028)

As per the research report, the size of the Europe Glycobiology Market was valued at USD 264.47 million in 2023 and estimated to be growing at a CAGR of 13.4%, to reach USD 495.96 million by 2028 during the forecast period 2023 to 2028.

Chronic diseases like cancer & diabetes have become a significant driver of drug development research, resulting in increased R&D spending by pharmaceutical companies, driving revenue growth in the Europe glycobiology market. Over the forecast period, the market's revenue growth is predicted to be boosted by increased financing from government bodies.

Increased demand for curative treatments for numerous life-threatening diseases, such as cancer, is predicted to accelerate the speed of pharmaceutical and biotechnological R&D, as well as overall spending in the glycobiology market. This makes glycobiology an appealing investment opportunity for big pharma and biotech companies. Furthermore, glycomic biomarkers have various uses in medication development and diagnostics for multiple disorders. Anti-cancer medication development has opened up new opportunities in the field of glycobiology.

Anti-infection medications are also produced with a high level of resiliency across the pharmaceutical industry. Clinical trials for anti-infection and anti-inflammatory drugs are expected to bring new market growth potential. In addition, Glycan's complicated structure has prompted medical experts to devote time and resources to studying them. This trend will help vendors in the glycobiology market to better position themselves. Furthermore, there is a growing interest in glycomics and proteomics research initiatives, which is expected to drive market growth shortly.

The Europe glycobiology market's revenue growth is hampered by high production costs and a scarcity of experienced personnel. These procedures necessitate the use of pricey instruments. The cost of regulation and maintenance for these devices is also high, limiting market growth during the projection period. X-ray crystallography and NMR spectroscopy are expensive, demanding, and time-consuming to thoroughly investigate complex glycans.

Over the forecast period, these restrictions are expected to limit market growth to some extent. A significant amount of money is invested in developing its products, and the approval of newly created pharmaceuticals necessitates several regulatory steps. As a result, these products are pretty costly.

This research report on the Europe Glycobiology Market has been segmented and sub-segmented into the following categories.

By Product:

  • Enzymes
  • Instruments
  • Kits & Reagents

By Application:

  • Diagnostic
  • Drug Discovery
  • Oncology

By End User:

  • Academic Research Institutions
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations   

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, Europe Glycobiology Market is expected to be the second-largest market for glycobiology. Research work at the University of Debrecen was financed by the National Research and Development and Innovation Office of Hungary and the European Regional Development Fund in February 2022.

The U.K Glycobiology Market is expected to proliferate due to the increased demand for glycomics approaches has resulted from a rise in the number of government initiatives aimed at increasing R&D funding.

The German Glycobiology Market is estimated to reach a significant growth due to the demand for glycomics research techniques to undertake through glycome studies growing all the time. In addition, biotech businesses are increasing their R&D investments as drug discovery and development become more common.

Drug development has become a critical part of medical research. Furthermore, active drug components are thoroughly investigated before being licensed for use in drug research. The utilization of common medications like heparin and erythropoietin to demonstrate the efficacy of glycans has emerged as a crucial market growth factor.


Key players dominating the Europe Glycobiology Market profiled in this report are Bruker Corporation, Takara Bio, Inc., Thermo Fisher Scientific and Waters Corporation, Danaher Corporation, New England Biolabs, ProZyme, Inc., Shimadzu Corporation, Merck KGaA (Germany), Agilent Technologies.,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample